A recent large prospective study found that the subgroup of HER2-low-positive tumours survived longer than the HER2-zero subgroup after receiving neoadjuvant combination chemotherapy and may serve as a novel molecular subgroup for the clinical treatment of breast cancer [30]. This evidence concerns the gene ERBB2 and breast carcinoma.